Related Experiment Video
Updated: Oct 17, 2025

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Hydrochlorothiazide Reduces Cardiac Hypertrophy, Fibrosis and Rho-Kinase Activation in DOCA-Salt Induced Hypertension
David Mondaca-Ruff1, Patricio Araos1,2, Cristián E Yañez1
1Laboratory of Molecular Cardiology, Division of Cardiovascular Diseases, School of Medicine, 60709Pontificia Universidad Católica de Chile, Santiago, Chile.
Insights
Hydrochlorothiazide (HCTZ) reduces hypertension-related myocardial remodeling by lowering blood pressure and inhibiting Rho-kinase (ROCK) activation. This study shows HCTZ effectively decreases cardiac hypertrophy and fibrosis in preclinical hypertension models.
Area of Science:
- Cardiovascular Pharmacology
- Renal Physiology
- Molecular Cardiology
Background:
- Thiazides, particularly hydrochlorothiazide (HCTZ), are widely used antihypertensive medications.
- The Rho/Rho-kinase (ROCK) pathway is implicated in cardiovascular remodeling processes.
- This study investigated the effect of HCTZ on ROCK activation in preclinical hypertension.
Purpose of the Study:
- To determine if HCTZ reduces myocardial Rho/Rho-kinase (ROCK) activation in a preclinical model of hypertension.
- To assess the impact of HCTZ on myocardial hypertrophy, fibrosis, and gene expression related to remodeling and oxidative stress.
- To compare the effects of HCTZ with a ROCK inhibitor (fasudil) and spironolactone.
Main Methods:
- A deoxycorticosterone (DOCA)-salt hypertension model in male Sprague-Dawley rats was utilized.
- Rats were treated with HCTZ, fasudil, or spironolactone for 3 weeks.
- Evaluations included blood pressure, myocardial hypertrophy and fibrosis, cardiac protein and mRNA levels, and ROCK activity.
Main Results:
- HCTZ, fasudil, and spironolactone significantly reduced blood pressure, myocardial hypertrophy, and fibrosis.
- These treatments also decreased cardiac levels of pro-fibrotic proteins (Col-I, Col-III, TGF-β1) and expression of pro-remodeling and pro-oxidative genes.
- HCTZ effectively reduced elevated myocardial ROCK activity to control levels.
Conclusions:
- HCTZ mitigates pathological left ventricular hypertrophy (LVH) by controlling blood pressure and reducing myocardial ROCK activation.
- HCTZ decreases myocardial fibrosis and expression of pro-remodeling, pro-fibrotic, and pro-oxidative genes.
- The observed effects of HCTZ on the myocardium may explain the preventive role of thiazides in hypertension, particularly in LVH regression and heart failure prevention.
Background:
Thiazides are one of the most common antihypertensive drugs used for hypertension treatment and hydrochlorothiazide (HCTZ) is the most frequently used diuretic for hypertension treatment. The Rho/Rho-kinase (ROCK) path plays a key function in cardiovascular remodeling. We hypothesized that in preclinical hypertension HCTZ reduces myocardial ROCK activation and consequent myocardial remodeling.
Methods:
The preclinical model of deoxycorticosterone (DOCA)-salt hypertension was used (Sprague-Dawley male rats). After 3 weeks, in 3 different groups: HCTZ, the ROCK inhibitor fasudil or spironolactone was added (3 weeks). After 6 weeks myocardial hypertrophy and fibrosis, cardiac levels of profibrotic proteins, mRNA levels (RT PCR) of pro remodeling and pro oxidative molecules and ROCK activity were determined.
Results:
Blood pressure, myocardial hypertrophy and fibrosis were reduced significantly by HCTZ, fasudil and spironolactone. In the heart, increased levels of the pro-fibrotic proteins Col-I, Col-III and TGF-β1 and gene expression of pro-remodeling molecules TGF-β1, CTGF, MCP-1 and PAI-1 and the pro-oxidative molecules gp91phox and p22phox were significantly reduced by HCTZ, fasudil and spironolactone. ROCK activity in the myocardium was increased by 54% (P < 0.05) as related to the sham group and HCTZ, spironolactone and fasudil, reduced ROCK activation to control levels.
Conclusions:
HCTZ reduced pathologic LVH by controlling blood pressure, hypertrophy and myocardial fibrosis and by decreasing myocardial ROCK activation, expression of pro remodeling, pro fibrotic and pro oxidative genes. In hypertension, the observed effects of HCTZ on the myocardium might explain preventive outcomes of thiazides in hypertension, specifically on LVH regression and incident heart failure.
Related Concept Videos
Heart Failure Drugs: Diuretics
Antihypertensive Drugs: Thiazide-Class Diuretics
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure V: Medical Management
Antihypertensive Drugs: Potassium-Sparing Diuretics
Antihypertensive Drugs: Action of Diuretics

